CMS to Negotiate Medicaid Outcomes-Based Agreements for Sickle Cell Gene Therapies

The Centers for Medicare and Medicaid Services will enter talks with manufacturers to come up with a pricing and rebate scheme that will tie the gene therapies’ cost with their effectiveness.

Scroll to Top